Browsing Tag
Inhibitor
4 posts
Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia
Meeting Coverage > ASH: Hematology — Rilzabrutinib specifically designed to reduce platelet-targeting autoantibodies by Ian Ingram, Managing Editor, MedPage Today December 8, 2024 SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), a phase III trial
Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer
Oncology/Hematology > Lung Cancer — Half of patients responded, but editorialists call for new directions in therapy development by Charles Bankhead, Senior Editor, MedPage Today June 11, 2024 A China-developed KRAS inhibitor led to objective responses in half of patients with previously treated KRAS-mutant non-small cell lung cancer (NSCLC), a prospective non-randomized trial showed. Overall
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
MainTherapeutic target identification is a crucial step of the drug-discovery pipeline for all disease processes, including fibrosis. Erroneous targets selected at the early stage of drug development may result in a costly drug-discovery program, often ending in failure during phase II trials years later1,2. As a result, large pharmaceutical companies may behave as though they
First AKT Inhibitor Approved for Advanced Breast Cancer
Oncology/Hematology > Breast Cancer — Capivasertib plus fulvestrant doubled progression-free survival versus fulvestrant-placebo by Charles Bankhead, Senior Editor, MedPage Today November 17, 2023 The FDA approved the first-in-class AKT inhibitor capivasertib (Truqap), in combination with fulvestrant, for locally advanced/metastatic hormone receptor (HR)-positive/HER2-negative breast cancer and at least one specific genetic alteration. The approval stipulates use